Cellectis vs Protalix BioTherapeutics
CLLS and PLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CLLS and PLX compare
Cellectis grew revenue faster over the last twelve months (75.8% versus 37.0% for Protalix BioTherapeutics).
Protalix BioTherapeutics keeps more of each dollar of sales as profit, with a net margin of 24.3% compared with −92.7% at Cellectis.
Protalix BioTherapeutics scores higher on the StockData Score (16 against 3 for Cellectis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CLLS | PLX |
|---|---|---|
| Size and price | ||
| Market cap | – | $246M |
| Share price | $1.18 | $3.05 |
| Change, 1 year | −67.7% | 42.5% |
| Change, 5 years | −86.8% | 211% |
| Beta (5Y) | 2.07 | 0.87 |
| Employees | 229 | 226 |
| StockData Score | ||
| Total score | 3 | 16 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 2 | 2 |
| Performance score | 1 | 4 (better) |
| Health score | 0 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 12.2× |
| P/S | – | 2.9× |
| P/B | – | 3.1× |
| EV/EBITDA | – | 8.9× |
| P/FCF | – | 16.3× |
| FCF yield | – | 6.1% |
| Fair value | – | $6.09 |
| Margin of safety | – | 49.9% |
| Growth | ||
| Revenue growth (TTM) | 75.8% (better) | 37.0% |
| Revenue growth, 5Y average | 7.4% (better) | −3.5% |
| Net income growth (TTM) | – | 281% |
| EPS growth (TTM) | – | 525% |
| Profitability | ||
| Gross margin | 100% (better) | 71.2% |
| Operating margin | −45.3% | 29.8% (better) |
| Net margin | −92.7% | 24.3% (better) |
| FCF margin | −57.2% | 17.8% (better) |
| Return on equity | −97.8% | 30.8% (better) |
| Return on invested capital | −122% | 41.0% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −0.6× | – |
| Current ratio | – | 3.27 |
| Altman Z-score | – | 6.03 |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 9.4% | 17.9% |
| Held by insiders | 53.4% | 3.8% |
| Insider net buying, 12 months | – | $101K |
| Short interest, % of float | – | 4.5% |
Go deeper
- CLLS stock overview
- CLLS income statement
- CLLS valuation and score
- PLX stock overview
- PLX income statement
- PLX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.